Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
무작위 임상시험
0/5 보강
APA
Azad AA, Fizazi K, et al. (2026). Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].. European journal of cancer (Oxford, England : 1990), 232, 116106. https://doi.org/10.1016/j.ejca.2025.116106
MLA
Azad AA, et al.. "Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].." European journal of cancer (Oxford, England : 1990), vol. 232, 2026, pp. 116106.
PMID
41259940 ↗